Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
暂无分享,去创建一个
P. Secchiero | F. Corallini | G. Zauli | V. Gattei | E. Rimondi | Paola Secchiero | Mario Tiribelli | Giorgio Zauli | Maria Grazia di Iasio | M. Tiribelli | Valter Gattei | Elisabetta Melloni | Erika Rimondi | Federica Corallini | E. Melloni | M. G. di Iasio
[1] P. Secchiero,et al. MDM2 Antagonist Nutlin‐3 Suppresses the Proliferation and Differentiation of Human Pre‐Osteoclasts Through a p53‐Dependent Pathway , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] M. Hilgarth,et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2 , 2005, Leukemia.
[3] T. Golde,et al. TCR-Mediated Notch Signaling Regulates Proliferation and IFN-γ Production in Peripheral T Cells 1 , 2003, The Journal of Immunology.
[4] I. Screpanti,et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.
[5] P. Secchiero,et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. , 2007, Current drug metabolism.
[6] R. Fanin,et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .
[7] Marina Konopleva,et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.
[8] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[9] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[10] M. Dettke,et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. , 2002, Blood.
[11] Hong Yang,et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.
[12] P. Secchiero,et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors , 2008, Journal of cellular physiology.
[13] S. Salati,et al. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects , 2008, Current opinion in hematology.
[14] G. Nilsson,et al. Distinct and regulated expression of Notch receptors in hematopoietic lineages and during myeloid differentiation , 2001, European journal of immunology.
[15] S. Hayashi,et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. , 2003, Blood.
[16] M. Nakao,et al. Transcriptional Blockade Induces p53-dependent Apoptosis Associated with Translocation of p53 to Mitochondria* , 2005, Journal of Biological Chemistry.
[17] P. Ojala,et al. p53 Reactivation Kills KSHV Lymphomas Efficiently In Vitro and In Vivo: New Hope for Treating Aggressive Viral Lymphomas , 2007, Cell cycle.
[18] M. Kaminski,et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.
[19] M. Vitale,et al. Thrombopoietin Enhances the αIIbβ3-Dependent Adhesion of Megakaryocytic Cells to Fibrinogen or Fibronectin Through PI 3 Kinase , 1997 .
[20] Chin-Tong Ong,et al. NOTCH1 Regulates Osteoclastogenesis Directly in Osteoclast Precursors and Indirectly via Osteoblast Lineage Cells* , 2008, Journal of Biological Chemistry.
[21] B. Dörken,et al. Notch signaling in leukemias and lymphomas. , 2008, Current molecular medicine.
[22] S. de Vos,et al. Modeling Notch Signaling in Normal and Neoplastic Hematopoiesis: Global Gene Expression Profiling in Response to Activated Notch Expression , 2007, Stem cells.
[23] M. Fujita,et al. Regulation of Notch1 Gene Expression by p53 in Epithelial Cells , 2007, Molecular and Cellular Biology.
[24] Taku Sato,et al. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells. , 2007, Oncology reports.
[25] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[26] L. Vassilev,et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. , 2008, Blood.
[27] S. Pavey,et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. , 2001, Molecular pharmacology.
[28] T. Park,et al. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation , 2007, Cell Death and Differentiation.
[29] P. Secchiero,et al. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. , 2004, Blood.
[30] Ying-hua Jin,et al. Caspase 3-mediated Cleavage of p21 WAF1/CIP1 Associated with the Cyclin A-Cyclin-dependent Kinase 2 Complex Is a Prerequisite for Apoptosis in SK-HEP-1 Cells* , 2000, The Journal of Biological Chemistry.
[31] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[32] Sathish Kumar Mungamuri,et al. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. , 2006, Cancer research.
[33] T. Honjo,et al. Conservation of the biochemical mechanisms of signal transduction among mammalian Notch family members , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] Gabriel Pons,et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.
[35] L. Jeffrey Medeiros,et al. Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.
[36] P. Secchiero,et al. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. , 2008, Current pharmaceutical design.
[37] P. Secchiero,et al. Tumour necrosis factor‐related apoptosis‐inducing ligand sequentially activates pro‐survival and pro‐apoptotic pathways in SK‐N‐MC neuronal cells , 2003, Journal of neurochemistry.
[38] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[39] L. Vassilev,et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.
[40] F. Alimirah,et al. Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. , 2007, Neoplasia.
[41] L. Vassilev,et al. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells , 2007, Leukemia.
[42] D. Dittmer,et al. Functional p53 Signaling in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas: Implications for Therapy , 2006, Journal of Virology.
[43] L. Reiniger,et al. Activity of the Notch‐signalling Pathway in Circulating Human Chronic Lymphocytic Leukaemia Cells , 2007, Scandinavian journal of immunology.
[44] S. Leach,et al. Notch in malignancy. , 2003, Cancer treatment and research.
[45] T. Golde,et al. TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. , 2003, Journal of immunology.
[46] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[47] L. Espinosa,et al. The notch pathway positively regulates programmed cell death during erythroid differentiation , 2007, Leukemia.
[48] Y. Okamoto,et al. SurveyorTM nuclease-based detection of p53 gene mutations in haematological malignancy , 2007, Annals of clinical biochemistry.
[49] Marina Konopleva,et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.